Johnson & Johnson
262,51 $Variazione rispetto alla chiusura precedente: −0,84%Variazione assoluta: −2,23 $
Ultime notizie
Titoli nella lingua originale della fonte.
- Johnson & Johnson vs. Eli Lilly: Which Pharma Stock Can Make Your Portfolio Healthier in 2026? (si apre in una nuova scheda)
- Bristol-Myers Squibb vs. Johnson & Johnson: Comparing Quarterly Revenue Scale (si apre in una nuova scheda)
- Johnson & Johnson (NYSE:JNJ) Raises Its Payout (si apre in una nuova scheda)
- Johnson & Johnson survey finds women not connecting menopause to eye health changes (si apre in una nuova scheda)
- History Says Johnson & Johnson Beats Medtronic. Here's Why I'd Still Consider MDT for the Next Decade. (si apre in una nuova scheda)
- New Global Survey by Johnson & Johnson Finds Most Women Don’t Connect Eye Health Changes with Menopause (si apre in una nuova scheda)
- New Global Survey by Johnson & Johnson Finds Most Women Don't Connect Eye Health Changes with Menopause (si apre in una nuova scheda)
- 5 High-Yield Dividend Stocks That Pass the Coverage Test (Not Just the Yield Test) (si apre in una nuova scheda)
- ABBV Stock Rises 25% in 6 Months: Time to Buy, Hold or Sell? (si apre in una nuova scheda)
- Johnson & Johnson (JNJ) Stock Could Be Undervalued On Future Cash Flow (si apre in una nuova scheda)
- What is Johnson & Johnson’s (JNJ) Economic Moat, and is it Widening or Narrowing? (si apre in una nuova scheda)
- 3 Reasons Johnson & Johnson Is Still a Buy With Its Stock Near a Record High (si apre in una nuova scheda)
- Was The Run In JNJ Stock Hiding In Plain Sight? (si apre in una nuova scheda)
- Microsoft vs. Johnson & Johnson: Which Dividend Will Pay You More in 10 Years? (si apre in una nuova scheda)
- Are You Overpaying For Pfizer Stock Versus Its Rivals? (si apre in una nuova scheda)
- Why Johnson & Johnson (JNJ) is a Great Dividend Stock Right Now (si apre in una nuova scheda)
- What Is Merck Stock's Biggest Opportunity? (si apre in una nuova scheda)
- BofA Boosts AbbVie and J&J Price Targets on Growth and Pipeline Strength (si apre in una nuova scheda)
- SCHD's Top Sector Bet Is Healthcare at 20.7%. I'm Not Sure What's More Surprising: What It Doesn't Hold, or What It Does. (si apre in una nuova scheda)
- Johnson & Johnson Gears Up For Q3 Print; Here Are The Recent Forecast Changes From Wall Street's Most Acc (si apre in una nuova scheda)
- What Does Johnson & Johnson (JNJ) Long Term IMAAVY Data Mean For gMG? (si apre in una nuova scheda)
- Johnson & Johnson (JNJ) Shares In Focus After New Adolescent gMG Data (si apre in una nuova scheda)
- Johnson & Johnson (JNJ) Sees a More Significant Dip Than Broader Market: Some Facts to Know (si apre in una nuova scheda)
- Do You Really Understand ISRG Stock's Risk? (si apre in una nuova scheda)
- Muse AI Agent Stock Portfolio: 2 Non-AI Stock Picks You Should Not Miss (si apre in una nuova scheda)
- Defensive Dividends: 3 Companies Investors Can Rely On (si apre in una nuova scheda)
- Is Eli Lilly Stock a Good Fit For Your Portfolio Risk? (si apre in una nuova scheda)
- Johnson & Johnson's psoriasis drug Icotyde could hit $4.5B in peak sales, BofA says (si apre in una nuova scheda)
- Johnson & Johnson Q3 Preview: Analyst Projects In-Line Sales, Earnings Miss (si apre in una nuova scheda)
- Johnson & Johnson Reports IMAAVY Myasthenia Gravis Data (si apre in una nuova scheda)